Akums Drugs and Pharmaceuticals Ltd disclosed a tax penalty order of ₹18 million against one manufacturing unit, likely GST or income tax related. The company plans to evaluate appeal options, maintaining operations unaffected amid prior tax department searches earlier in 2025.
Akums Drugs and Pharmaceuticals Ltd, India's third-largest CDMO, received a ₹1.8 crore tax penalty order for a specific manufacturing unit, as per recent regulatory disclosures. This follows January 2025 income tax searches at offices, plants, and executives' residences, where the firm cooperated fully without operational disruptions or disclosed demands at the time.
Penalty and Response Highlights:
-
Order targets single unit for unspecified tax discrepancies, totaling ₹18 million payable.
-
Akums assessing legal remedies including appeals, consistent with prior favorable CIT(A) rulings under Income Tax Act section 250.
-
No material financial impact expected; Q1 FY26 showed 19% EBITDA growth to ₹1,051 Cr revenue amid EU contracts and 1,000+ approvals.
The episode underscores ongoing tax vigilance in pharma amid robust growth, with shares minimally impacted post-IPO.
Sources: Economic Times Pharma, CNBC-TV18, Marketscreener, TaxTMI.